Effects of food and esomeprazole on pharmacokinetics of sevabertinib
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/apxd7137 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Ahmed Elsayed und 11 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
Sevabertinib (BAY 2927088) is an oral reversible tyrosine kinase inhibitor being developed for treatment of adult patients with unresectable or metastatic non-small cell lung cancer harboring human epidermal growth factor receptor 2–activating mutations. Sevabertinib is a high-permeability compound with low pH-dependent aqueous solubility. A clinical study was performed to evaluate the pharmacokinetics (PK) of sevabertinib when administered under fasted conditions or following a highor low-fat meal (NCT06378658). The effect of the proton pump inhibitor (PPI) esomeprazole was also evaluated.
Zitieren
APA
Elsayed, A., Brennan, B. J., Damaske, M., Hafner, F., Muenster, U., Lender, A., Joseph, J., Reif, S., Prendergast, S., Lienau, P., Ploeger, B., & Chen, C. (2026). Effects of food and esomeprazole on pharmacokinetics of sevabertinib. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/apxd7137
Vancouver
Elsayed A, Brennan BJ, Damaske M, Hafner F, Muenster U, Lender A, et al. Effects of food and esomeprazole on pharmacokinetics of sevabertinib. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/apxd7137
BibTeX
@article{Elsayed2026,
author = {Elsayed, Ahmed and Brennan, Barbara J. and Damaske, Michaela and Hafner, Frank-Thorsten and Muenster, Uwe and Lender, Andreas and Joseph, Jan and Reif, Stefanie and Prendergast, Sue and Lienau, Philip and Ploeger, Bart and Chen, Chunlin},
title = {Effects of food and esomeprazole on pharmacokinetics of sevabertinib},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/apxd7137}
}
EUVIMED